Overview / Wet lab and cell therapy
Wet lab and cell therapy
I engineer and assay primary human NK and CD8 T cells, design high-parameter flow cytometry panels, and run the preclinical models behind my analyses. My research looks at why NK and CD8 T cells lose function in tumours, and how to make cell therapies more effective.
- flow cytometry
- 40+ colours
- engineered in primary cells
- NK, CD8
- sole-PI grant
- €100k
Techniques
- Flow cytometry
- Spectral (Cytek Aurora, Sony ID7000) and conventional cytometry (BD LSRFortessa, FACSymphony); 40+ colour panel design and validation; FACS sorting (BD FACSAria, Sony SH800); high-dimensional analysis (FlowSOM, UMAP, Spectre); core-facility training and support.
- Cell engineering
- CRISPR knock-out and knock-in in primary human NK and CD8 T cells; lentiviral and adenoviral overexpression; electroporation; CAR-NK and CAR-T; primary NK and T cell isolation and expansion; engineered and reporter cell lines.
- Functional assays
- Cytotoxicity by flow, luciferase and LDH, real-time killing (xCELLigence, IncuCyte) and serial killing, including spheroid and organoid targets; antigen-specific T cell assays (peptide, tetramer and dextramer); metabolic assays (Seahorse, SCENITH); dose-response analysis.
- Preclinical models
- Syngeneic and humanised tumour models; LCMV acute and chronic infection; adoptive transfer; knockout and reporter lines; in vivo imaging (IVIS); study design with power calculation, randomisation and blinding.
- Human tissue and culture
- Tumour, healthy tissue and PBMC processing; liver and intraepithelial lymphocyte isolation; air–liquid interface organoids and tissue fragment cultures; STR and mycoplasma QC.
- Molecular methods
- DNA and RNA extraction, PCR and qPCR, genotyping; Western blot, ELISA, ELISpot.
Immunology focus
- Cells
- NK cells and innate lymphoid cells; unconventional T cells (MAIT, NKT, γδ and intraepithelial); CD8 and CD4 T cells.
- Cancer and therapy
- Tumour microenvironment and T cell exhaustion; checkpoint blockade; adoptive cell therapy (TIL, CAR-T, CAR-NK, TCR-engineered T cells); innate immunotherapy; biomarkers of response.
- Infection and tissue
- LCMV, EBV, CMV and influenza immunity; tissue-resident and liver immunity; type I interferon signalling; immunometabolism; thymic development.
Cell therapy track record
- PaperT cell repertoire remodelling following post-transplant T cell therapy coincides with clinical response Journal of Clinical Investigation 2019
- PaperThe NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation Nature Immunology 2020
- PaperNKG7 is required for optimal antitumor T-cell immunity Cancer Immunology Research 2022
- PaperRegulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy Haematologica 2024
- PaperCXCL12 inhibition with radiotherapy in glioblastoma: phase I/II GLORIA trial Nature Communications 2024
- PaperType I interferon drives a cellular state inert to TCR stimulation European Journal of Immunology 2025, first author
- GrantBMBF GO-Bio Initial · €100k · sole PI
- PatentProvisional AU 2017904567 · immunocompetence biomarkers